BioNTech SE (BNTX) Reports Q2 EPS of EUR6.45
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Clear Street Starts Forgent Power Solutions (FPS) at Buy
BioNTech SE (BNTX) Slides on Vaccine Revenue Miss But Consensus Was 'Too High'
August 8, 2022 3:32 PM EDTBioNTech SE (NASDAQ: BNTX) shares tumbled more than 9% Monday after reporting second-quarter earnings before the open.
The drugmaker posted second-quarter earnings of 6.45 per share on revenue of 3.2 billion. Earnings and revenue fell from the second quarter of 2021, where it reported a profit of 10.77 per share on revenue of $5.3 billion.
"With our strong performance year to date, we believe to be well on track to achieve our previous financial guidance for the ongoing financial year,"... More



